Pembrolizumab for Heavily Pretreated Patients With Advanced Carcinoma of the Esophagus
This phase 2, open-label, interventional study examined the safety and efficacy of pembrolizumab for patients with advanced, metastatic esophageal carcinoma that has progressed after 2 or more lines of systemic therapy.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου